Status:
COMPLETED
The Multi-Sensor Distance Accuracy Study
Lead Sponsor:
Oregon Health and Science University
Collaborating Sponsors:
The Leona M. and Harry B. Helmsley Charitable Trust
Conditions:
Type 1 Diabetes Mellitus
Eligibility:
All Genders
18-65 years
Brief Summary
The purpose of the study is to test the accuracy benefit of having two glucose sensors (over one sensor alone) when they are positioned: 2mm, 10mm, 20mm, or 30mm apart. It is not yet known how close t...
Detailed Description
An artificial pancreas system will likely require multiple glucose sensing elements to function safely. It is not yet known how close two glucose sensors can be placed and still work properly. Meaning...
Eligibility Criteria
Inclusion
- Type 1 diabetes mellitus diagnosed for at least 6 months
- Current usage of multiple daily injections or subcutaneous insulin pump treatment
- Age 18-65 years
- HbA1c of 6.0 - 9.5% at screening visit
- BMI 21-35
- Willingness to follow all study procedures, including attending all clinic visits
- Willingness to sign informed consent and HIPAA documents
Exclusion
- Subjects presenting with any of the following will not be included in the study.
- Pregnancy or Lactation: for women of childbearing potential there is a requirement for a negative urine pregnancy test.
- Renal insufficiency (serum creatinine of 2.0 mg/dL or greater). Serum ALT or AST equal to or greater than 3 times the upper limit of normal; hepatic synthetic insufficiency as defined as a serum albumin of less the 3.3 g/dL; or serum bilirubin of over 2.
- Hematocrit of less than or equal to 34%.
- Congestive heart failure, NYHA class III or IV.
- Visual impairment preventing reading of glucose meter values.
- Active coronary artery disease as manifested by unstable angina, or a myocardial infarction or therapeutic coronary percutaneous procedure (e.g., PTCA, stent placement) or CABG within the past 4 months.
- Active foot ulceration.
- Severe peripheral arterial disease characterized by ischemic rest pain or severe claudication.
- Cerebrovascular accident within the past 6 months.
- Active alcohol abuse, substance abuse, or severe mental illness (as judged by the principal investigator).
- Active malignancy, except basal cell or squamous cell skin cancers.
- Major surgical operation within 30 days prior to screening.
- Seizure disorder (epilepsy).
- Any concurrent illness, other than diabetes, that is not controlled by a stable therapeutic regimen.
- Currently administration of oral or parenteral corticosteroids.
- Use of an investigational drug within 30 days prior to screening.
- Bleeding disorder, treatment with warfarin, or platelet count below 50,000.
Key Trial Info
Start Date :
July 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2011
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT02241993
Start Date
July 1 2010
End Date
January 1 2011
Last Update
September 16 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oregon Health & Science University
Portland, Oregon, United States, 97239